Acuta Capital Partners, LLC United Therapeutics Corp Transaction History

Acuta Capital Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$212.99 - $276.17 $2.02 Million - $2.62 Million	-9,500 Reduced 28.79%	23,500 $5.26 Million
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $1.13 Million - $1.54 Million	5,500 Added 20.0%	33,000 $9.18 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $2.95 Million - $3.54 Million	14,500 Added 111.54%	27,500 $5.76 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $2.27 Million - $3.13 Million	13,000 New	13,000 $3.06 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $552,960 - $648,240	-3,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $539,580 - $644,640	3,000 New	3,000 $554,000

676

42.1M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.